Live-attenuated Chikungunya vaccine: a possible new era

Affiliations

Comment

Kathryn E Stephenson. Lancet. 2023.

. 2023 Jun 24;401(10394):2090-2091.

doi: 10.1016/S0140-6736(23)01170-4. Epub 2023 Jun 12.

¹ Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Electronic address: kstephen@bidmc.harvard.edu.

No abstract available

Conflict of interest statement

I declare no competing interests.

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, Hochreiter R, Bitzer A, Kosulin K, Larcher-Senn J, Mader R, Dubischar K, Zoihsl O, Jaramillo JC, Eder-Lingelbach S, Buerger V, Wressnigg N. Schneider M, et al. Lancet. 2023 Jun 24;401(10394):2138-2147. doi: 10.1016/S0140-6736(23)00641-4. Epub 2023 Jun 12. Lancet. 2023. PMID: 37321235 Free PMC article. Clinical Trial.